Toca 5 Clinical Trial

Brain cancers, such as glioblastoma (GBM) and anaplastic astrocytoma (AA), often regrow despite initial treatment. Participation in a clinical trial is one possible option for people who have regrowth of these types of brain cancers. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.

Tocagen is developing a cancer-selective virus for the treatment of cancer. The company is conducting a clinical trial, called Toca 5, for patients with recurrent GBM or recurrent AA who are planning to have their tumor removed surgically.

A patient may qualify for this study if the patient:

  • has glioblastoma or anaplastic astrocytoma at 1st or 2nd recurrence (including this recurrence)
  • has had prior surgery, radiation and chemotherapy
  • is between 18 years old and 75 years old

This study is ongoing in the United States, Canada, Israel and South Korea. View a list of participating sites.

Learn more about the study including a full list of entry criteria.

Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.